Sequencing of gyrase and topoisomerase IV quinolone-resistance- determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro

103Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The L2 reference strain of Chlamydia trachomatis was exposed to subinhibitory concentrations of ofloxacin (0.5 μg/ml) and sparfloxacin (0.015 μg/ml) to select fluoroquinolone-resistant mutants. In this study, two resistant strains were isolated after four rounds of selection. The C. trachomatis mutants presented with high-level resistance to various fluoroquinolones, particularly to sparfloxacin, for which a 1,000-fold increase in the MICs for the mutant strains compared to the MIC for the susceptible strain was found. The MICs of unrelated antibiotics (doxycycline and erythromycin) for the mutant strains were identical to those for the reference strain. The gyrase (gyrA, gyrB) and topoisomerase IV (parC, parE) genes of the susceptible and resistant strains of C. trachomatis were partially sequenced. A point mutation was found in the gyrA quinolone- resistance-determining region (QRDR) of both resistant strains, leading to a Ser83→Ile substitution (Escherichia coli numbering) in the corresponding protein. The gyrB, parC, and pare QRDRs of the resistant strains were identical to those of the reference strain. These results suggest that in C. trachomatis, DNA gyrase is the primary target of ofloxacin and sparfloxacin.

Cite

CITATION STYLE

APA

Dessus-Babus, S., Bébéar, C. M., Charron, A., Bébéar, C., & De Barbeyrac, B. (1998). Sequencing of gyrase and topoisomerase IV quinolone-resistance- determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrobial Agents and Chemotherapy, 42(10), 2474–2481. https://doi.org/10.1128/aac.42.10.2474

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free